These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 36451865)

  • 1. Development of functional nanomedicines for tumor associated macrophages-focused cancer immunotherapy.
    Wei X; Wang J; Liang M; Song M
    Theranostics; 2022; 12(18):7821-7852. PubMed ID: 36451865
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent Progress on Nanomedicine-Mediated Repolarization of Tumor-Associated Macrophages for Cancer Immunotherapy.
    Zhang JY; Su YH; Wang X; Yao X; Du JZ
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2024; 16(5):e2001. PubMed ID: 39425549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanomedicine-based cancer immunotherapies developed by reprogramming tumor-associated macrophages.
    Li X; Guo X; Ling J; Tang Z; Huang G; He L; Chen T
    Nanoscale; 2021 Mar; 13(9):4705-4727. PubMed ID: 33625411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tailoring Nanomaterials for Targeting Tumor-Associated Macrophages.
    Ovais M; Guo M; Chen C
    Adv Mater; 2019 May; 31(19):e1808303. PubMed ID: 30883982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanomedicines Targeting Tumor Cells or Tumor-Associated Macrophages for Combinatorial Cancer Photodynamic Therapy and Immunotherapy: Strategies and Influencing Factors.
    Wei Y; Li R; Wang Y; Fu J; Liu J; Ma X
    Int J Nanomedicine; 2024; 19():10129-10144. PubMed ID: 39381025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer Immunotherapy: Targeting Tumor-Associated Macrophages by Gene Silencing.
    Zins K; Abraham D
    Methods Mol Biol; 2020; 2115():289-325. PubMed ID: 32006408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanomaterials in modulating tumor-associated macrophages and enhancing immunotherapy.
    Liang C; Zhang Y; Wang S; Jiao W; Guo J; Zhang N; Liu X
    J Mater Chem B; 2024 May; 12(20):4809-4823. PubMed ID: 38695349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanomaterials-Involved Tumor-Associated Macrophages' Reprogramming for Antitumor Therapy.
    Li SL; Hou HY; Chu X; Zhu YY; Zhang YJ; Duan MD; Liu J; Liu Y
    ACS Nano; 2024 Mar; 18(11):7769-7795. PubMed ID: 38420949
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting tumor associated macrophages: The new challenge for nanomedicine.
    Andón FT; Digifico E; Maeda A; Erreni M; Mantovani A; Alonso MJ; Allavena P
    Semin Immunol; 2017 Dec; 34():103-113. PubMed ID: 28941641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nanomedicine enables spatiotemporally regulating macrophage-based cancer immunotherapy.
    Zhao YD; Muhetaerjiang M; An HW; Fang X; Zhao Y; Wang H
    Biomaterials; 2021 Jan; 268():120552. PubMed ID: 33307365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combining Nanomedicine and Immunotherapy.
    Shi Y; Lammers T
    Acc Chem Res; 2019 Jun; 52(6):1543-1554. PubMed ID: 31120725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor Associated Macrophages and TAMs-Based Anti-Tumor Nanomedicines.
    Cheng Y; Song S; Wu P; Lyu B; Qin M; Sun Y; Sun A; Mu L; Xu F; Zhang L; Wang J; Zhang Q
    Adv Healthc Mater; 2021 Sep; 10(18):e2100590. PubMed ID: 34292673
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progress in Tumor-Associated Macrophages: From Bench to Bedside.
    Wang Y; Lin YX; Qiao SL; Wang J; Wang H
    Adv Biosyst; 2019 Feb; 3(2):e1800232. PubMed ID: 32627370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Macrophage-modulating nanomedicine for cancer immunotherapy.
    Khan MM; Li Y; Zhou Z; Ni A; Saiding Q; Qin D; Tao W; Chen W
    Nanoscale; 2024 Apr; 16(15):7378-7386. PubMed ID: 38511468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor-Targeted Nanomedicine for Immunotherapy.
    Cabral H; Kinoh H; Kataoka K
    Acc Chem Res; 2020 Dec; 53(12):2765-2776. PubMed ID: 33161717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted delivery of zoledronic acid through the sialic acid - Siglec axis for killing and reversal of M2 phenotypic tumor-associated macrophages - A promising cancer immunotherapy.
    Tang X; Sui D; Liu M; Zhang H; Liu M; Wang S; Zhao D; Sun W; Liu M; Luo X; Lai X; Liu X; Deng Y; Song Y
    Int J Pharm; 2020 Nov; 590():119929. PubMed ID: 33010395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting tumor-associated macrophages for cancer immunotherapy.
    Shu Y; Cheng P
    Biochim Biophys Acta Rev Cancer; 2020 Dec; 1874(2):188434. PubMed ID: 32956767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor-Associated Macrophage Targeting of Nanomedicines in Cancer Therapy.
    Kang X; Huang Y; Wang H; Jadhav S; Yue Z; Tiwari AK; Babu RJ
    Pharmaceutics; 2023 Dec; 16(1):. PubMed ID: 38258072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting tumor-associated macrophages for cancer immunotherapy.
    Cao X; Lai SWT; Chen S; Wang S; Feng M
    Int Rev Cell Mol Biol; 2022; 368():61-108. PubMed ID: 35636930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reprogramming Hypoxic Tumor-Associated Macrophages by Nanoglycoclusters for Boosted Cancer Immunotherapy.
    Zhao YD; An HW; Mamuti M; Zeng XZ; Zheng R; Yang J; Zhou W; Liang Y; Qin G; Hou DY; Liu X; Wang H; Zhao Y; Fang X
    Adv Mater; 2023 Jun; 35(24):e2211332. PubMed ID: 36971342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.